Literature DB >> 28643750

Evaluation of clinical process in osteosarcoma patients treated with chemotherapy including cisplatin, adriamycin, ifosfamide, and etoposide and determination of the treatment sequels in a long-term 11-year follow-up.

Mozaffar Aznab1, Maryam Hematti2.   

Abstract

AIM: The aim of this study was to evaluate the effect of adding etoposide and ifosfamide chemotherapy drugs to treatment regimen of patients affected with osteosarcoma and to determine the clinical process and response to treatment during a follow-up period of 11 years.
MATERIALS AND METHODS: Forty patients with osteosarcoma participated in this study from July 2005 to 2016. Treatments were started based on the following schema and after initial examinations including biochemical profile, checking for lung metastasis by simple radiography, chest computed tomography scan, and bones scan. The initial chemotherapy which consisted of four cycles of cisplatin and adriamycin alternative with ifosfamide and etoposide was provided. Afterward, resection of the primary tumor and also the metastatic lesions was performed in patients with lung metastasis in case they had radiological evidence of response to the treatment.
RESULTS: The mean of follow-up duration in this study was 50 months. Thirty-four patients did not have metastasis and six were metastatic. Of 34 patients, 18 had relapse and 16 patients never had relapse. Five patients experienced only local relapse, nine had only systemic relapse, and two patients had simultaneous systemic and local relapses. Thirteen patients had died. The mean of overall survival in patients was 81 months. The mean of survival in patients with and without primary metastasis was 30 and 90 months, respectively.
CONCLUSION: Favorable response to the treatment was obtained with an appropriate multiple disciplinary works in the osteosarcomas of extremities, and there were no considerable side effects and sequels in the long-term follow-up of these treatments.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28643750     DOI: 10.4103/0973-1482.199447

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  6 in total

Review 1.  Osteosarcoma: a review of current and future therapeutic approaches.

Authors:  Xin Zhao; Qirui Wu; Xiuqing Gong; Jinfeng Liu; Yujie Ma
Journal:  Biomed Eng Online       Date:  2021-03-02       Impact factor: 2.819

2.  Expression of Livin and PlGF in human osteosarcoma is associated with tumor progression and clinical outcome.

Authors:  Kuo Sun; Qi Liao; Zenggan Chen; Tongyi Chen; Jian Zhang
Journal:  Oncol Lett       Date:  2018-07-31       Impact factor: 2.967

3.  Development and validation of a nomogram for osteosarcoma-specific survival: A population-based study.

Authors:  Jun Zhang; Jin Yang; Hai-Qiang Wang; Zhenyu Pan; Xiaoni Yan; Chuanyu Hu; Yuanjie Li; Jun Lyu
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

4.  Nucleus size and DNA accessibility are linked to the regulation of paraspeckle formation in cellular differentiation.

Authors:  Markus Grosch; Sebastian Ittermann; Ejona Rusha; Tobias Greisle; Chaido Ori; Dong-Jiunn Jeffery Truong; Adam C O'Neill; Anna Pertek; Gil Gregor Westmeyer; Micha Drukker
Journal:  BMC Biol       Date:  2020-04-22       Impact factor: 7.431

Review 5.  Origin and Therapies of Osteosarcoma.

Authors:  Brice Moukengue; Morgane Lallier; Louise Marchandet; Marc Baud'huin; Franck Verrecchia; Benjamin Ory; Francois Lamoureux
Journal:  Cancers (Basel)       Date:  2022-07-19       Impact factor: 6.575

6.  Investigating the Relationship between of Vascular Endothelial Growth Factor and HER-2neu in IHC Staining with Metastasis and Mortality in Patients with Osteosarcoma.

Authors:  Mozaffar Aznab; Meisam Khajevand Ahmady; Khodamrad Jamshidi; Seyed Hamid Madani; Sdigheh Khazaei; Tina Shoushtaryzadeh; Abolfazl Bagheri
Journal:  Asian Pac J Cancer Prev       Date:  2020-10-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.